Frederick R Appelbaum
Overview
Explore the profile of Frederick R Appelbaum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
334
Citations
19350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
12.
Appelbaum F
Best Pract Res Clin Haematol
. 2023 Dec;
36(4):101518.
PMID: 38092471
The goal of a disease classification system is (or should be) to provide a tool for researchers and clinicians to study and treat the disease. The last decade has seen...
13.
Garcia-Manero G, Podoltsev N, Othus M, Pagel J, Radich J, Fang M, et al.
Leukemia
. 2023 Nov;
38(1):58-66.
PMID: 37935977
Prior experience indicated that use of higher doses of cytarabine during induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor resulted in high response rates. S1203 was a...
14.
Zarnegar-Lumley S, Alonzo T, Gerbing R, Othus M, Sun Z, Ries R, et al.
Blood Adv
. 2023 Jun;
7(19):5941-5953.
PMID: 37267439
Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study was to describe the...
15.
Termini C, Moseley A, Othus M, Appelbaum F, Chauncey T, Erba H, et al.
Haematologica
. 2023 Apr;
108(11):3148-3151.
PMID: 37021537
No abstract available.
16.
Pogosova-Agadjanyan E, Hua X, Othus M, Appelbaum F, Chauncey T, Erba H, et al.
Biomark Res
. 2023 Mar;
11(1):31.
PMID: 36927800
Background: Studies have not systematically compared the ability to verify performance of prognostic transcripts in paired bulk mononuclear cells versus viable CD34-expressing leukemic blasts from patients with acute myeloid leukemia....
17.
Orvain C, Rodriguez-Arboli E, Othus M, Sandmaier B, Deeg H, Appelbaum F, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672303
(1) Background: Secondary acute myeloid leukemia (AML), i.e., AML arising from prior therapy (therapy-related) and/or an antecedent hematologic disorder (AHD) is generally associated with worse outcomes compared to de novo...
18.
Aldoss I, Yin J, Wall A, Mrozek K, Liedtke M, Claxton D, et al.
Blood Adv
. 2022 Oct;
7(2):196-204.
PMID: 36269846
Asparaginase is a key component of pediatric-inspired regimens in young adults with acute lymphoblastic leukemia (ALL). Truncation of asparaginase therapy is linked to inferior outcomes in children with ALL. However,...
19.
Sorror M, Gooley T, Storer B, Gerds A, Sekeres M, Medeiros B, et al.
Blood
. 2022 Oct;
141(3):295-308.
PMID: 36260765
We designed a prospective, observational study enrolling patients presenting for treatment of acute myeloid leukemia (AML) at 13 institutions to analyze associations between hematopoietic cell transplantation (HCT) and survival, quality...
20.
Orvain C, Byelykh M, Othus M, Sandmaier B, Schoch G, Davis C, et al.
Transplant Cell Ther
. 2022 Sep;
28(12):846.e1-846.e9.
PMID: 36179985
Pretransplantation nutritional status may impact outcome after allogeneic hematopoietic cell transplantation (HCT). Various simple screening tools have been developed and used to identify patients at risk of malnutrition; however, how...